Bremen, March 8, 2011 – Based on its preliminary figures for 2010, MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading software company in the field of image-based medicine, produced turnover of approximately EUR 14.4 million (previous year: EUR 13.9 million) and produced EBIT of around EUR -6 million (previous year: EUR 1.6 million) as earnings were negatively affected by non-cash special items. EBIT before special items came to roughly EUR 0.3 million.
These special items consist of two elements. One is the impairment loss of around EUR 5.5 million on intangible assets resulting from the acquisition of the pulmonary CT business at the end of 2008. This consists of about EUR 4.3 million for the complete write-off of this segment’s value and some EUR 1.2 million for the amortized costs of the software, licenses and customer base obtained during the transaction. Intangible assets were depreciated due to the disappointing sales performance. However, the Executive Board expects market potential in the middle and long term. The other element arises from establishing a provision of EUR 0.8 million for an obligatory grant to be paid to a research partner, which has increased the company’s other expenses. In previous years, this obligatory grant had been listed as a financial obligation in the company’s financial statements.
Further preliminary figures for the fiscal year just ended are available in the company’s corporate news release, issued today. The complete consolidated financial statement, group management report and 2011 forecast will be released on April 19, 2011.